# US 2024/0197894 A1 · Recombinant human serum albumin-therapeutic drug conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197894 A1
- Document ID: US20240197894A1
- Status: Published application
- Kind: A1
- Application number: 18/117,661
- Filed: 2023-03-06
- Published: 2024-06-20
- Earliest claimed: 2022-11-24
- Assignees: Wuhan Healthgen Biotechnology Corp
- Applicants: Wuhan Healthgen Biotechnology Corp.
- Inventors: Liangliang DONG; Daichang YANG; Jun XIA; Rong CHEN; Chuan SHI
- Web page: https://patentgrep.com/patent/US20240197894A1

## CPC

- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a drug conjugate of recombinant human serum albumin and a therapeutic drug. The drug conjugate is formed by covalent coupling a therapeutic drug to a free sulfhydryl group at position 34 of recombinant human serum albumin via a heterobifunctional linker. The drug conjugate of the present invention not only enhances the pharmacological action and improves the pharmacokinetics of the therapeutic drug, but also significantly increases the coupling efficiency of the therapeutic drug to human serum albumin, thereby reducing the production cost of the drug conjugate.

## Claims

### Claim 1

A drug-linker-albumin conjugate comprising:
(a) a recombinant human serum albumin;
(b) a therapeutic drug, and
(c) a heterobifunctional linker,
wherein the drug conjugate has a structure comprising: the recombinant human serum albumin is conjugated or linked to the therapeutic drug molecule by the heterobifunctional linker,
wherein a sulfhydryl group at position 34 of the recombinant human serum albumin is covalently coupled to the therapeutic drug by the heterobifunctional linker.

### Claim 2 (depends on 1)

The drug-linker-albumin of claim 1, wherein the recombinant human serum albumin is a recombinantly expressed in vitro.

### Claim 3 (depends on 1)

The drug-linker-albumin of claim 1, wherein the recombinant human serum albumin is a plant-derived or plant expressed recombinant human serum albumin.

### Claim 4 (depends on 3)

The drug-linker-albumin of claim 3, wherein the plant-derived recombinant human serum albumin is a recombinant human serum albumin expressed in rice seeds, yeast or a rice endosperm cell.

### Claim 5 (depends on 1)

The drug-linker-albumin of claim 1, wherein the heterobifunctional linker has bifunctional groups which comprise a reactive-to-sulfhydryl group and a group reactive to one of amino, hydroxyl, carbonyl and carboxyl.

### Claim 6 (depends on 5)

The drug-linker-albumin of claim 5, wherein the reactive-to-sulfhydryl group of the heterobifunctional linker is covalently coupled to the cysteine at position 34 of the recombinant human serum albumin, and the group reactive to one of amino, hydroxyl, carbonyl and carboxyl of the linker is covalently coupled to the therapeutic drug molecule.

### Claim 7 (depends on 1)

The drug-linker-albumin of claim 1, wherein the therapeutic drug molecule is a protein, polypeptide or small molecule compound with a molecular weight of less than about 80 kDa and without a free sulfhydryl group.

### Claim 8 (depends on 7)

The drug-linker-albumin of claim 7, wherein the therapeutic drug molecule is selected from the group consisting of: lactoferrin, a growth hormone, insulin, a parathyroid hormone (PTH), teriparatide, amphotericin B and a chemical drug derivative thereof.

### Claim 9 (depends on 1)

The drug-linker-albumin of claim 1, wherein the heterobifunctional linker comprises a 6-maleimidohexanoic acid N-hydroxysuccinimide ester.

### Claim 10 (depends on 1)

A method of preparing the drug-linker-albumin conjugate of claim 1, comprising the following steps of:
(1) covalently coupling a therapeutic drug molecule to one end of a heterobifunctional linker, thereby generating a therapeutic drug-linker conjugate;
(2) removing, or substantially removing, excess uncoupled heterobifunctional linker by desalting or chemical separation, thereby obtaining a preparation comprising a therapeutic drug-linker conjugate having no or substantially no excess uncoupled heterobifunctional linker; and
(3) adding a recombinant human serum albumin to the preparation under conditions wherein the recombinant human serum albumin chemically couples to the therapeutic drug-linker conjugate, thereby generating a therapeutic drug-linker-albumin conjugate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the heterobifunctional linker comprises 6-maleimidohexanoic acid N-hydroxysuccinimide ester.

### Claim 12 (depends on 10)

The method of claim 10, wherein the therapeutic drug reacts with the heterobifunctional linker at a molecular molar ratio of 1:5 in step (1), and in step (2) the recombinant human serum albumin reacts with the therapeutic drug-linker conjugate at a molecular molar ratio of 1:(0.2-1).
